ARVINAS - Key Persons
Job Titles:
- Member of the Senior Leadership Team
- Vice President of Oncology and Immuno - Oncology Research
Job Titles:
- Member of the Senior Leadership Team
- Senior Vice President of Global and U.S. Market Access
Mr. Santini is Senior Vice President of Global and U.S. Market Access at Arvinas. He has over 30 years of experience in driving successful product launches and customer service improvements while building strategic partnerships with key decision makers, both internally and externally.
Mr. Santini joins Arvinas after serving as Vice President Market Access, Trade & Channel Management at Merus, where he was responsible for ensuring all aspects of commercial launch readiness for their first commercial brand in Oncology.
Previously, Mr. Santini was Senior Vice President, Market Access, Trade & Channel Management at Nektar Therapeutics, and prior, he served as Executive Vice President, Chief Commercial Officer at Lexicon Pharmaceuticals where he was responsible for the commercial strategy. He also held roles of increasing responsibility across commercial and development at Bayer Healthcare, including serving as Executive Vice President, Managed Markets and Executive Committee Member.
Mr. Santini received his A.S. in Business Marketing from Westchester Community College and completed a Radiologic Technology Degree Program from the U.S. Air Force School of Health Care Science.
Job Titles:
- Member of the Senior Leadership Team
- Senior Vice President of Neuroscience and Platform Biology
Dr. Angela Cacace serves as Senior Vice President of Neuroscience and Platform Biology at Arvinas. Dr. Cacace brings more than two decades of biopharmaceutical research and pharmacology experience, contributing to four marketed drugs and over 18 development candidates. Previously, Dr. Cacace served as the Vice President of Biology at Fulcrum Therapeutics, where she built the biology platform and delivered the first development candidate for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Additionally, Dr. Cacace was the Director of Neuroscience and Genetically Defined Diseases at Bristol Myers Squibb, where she spearheaded alternative therapeutic modalities and was a co-inventor on several development candidates. Throughout her time at Bristol Myers Squibb, she was responsible for building research-wide teams and initiatives, including the Lead Profiling Function, GPCR High Throughput Screening Team and the Cellular Resource Team. While serving as a Sr. Principal Scientist in Cancer Biology at Pfizer, together with her team, she discovered a novel anti-angiogenic antibody development candidate.
Dr. Cacace received her B.S. in Biology from Fairfield University, Ph.D. in Pharmacology from Columbia University and completed her postdoctoral research in Oncology at Bristol Myers Squibb and the National Cancer Institute.
Dr. Benjamin Neel has strong experience in oncology, cancer cell signaling pathways, the role of pathway mutations, and their effects on disease development and cancer genomics. He serves as a Professor of Medicine at the NYU School of Medicine and Director of the Perlmutter Cancer Center at NYU Langone Health. Prior to joining NYU Langone, he served as Director of the Princess Margaret Cancer Center at University Health Network, which includes the Ontario Cancer Institute and Campbell Family Cancer Research Institute. Dr. Neel was also William B. Castle Professor of Medicine at Harvard Medical School. He is a Founder of Northern Biologics Inc. and previously served as a member of the Board of Directors. He is also a Founder of Navire Pharma, Inc. and the Chair of its Scientific Advisory Board. Dr. Neel previously served as a Director of the American Association of Cancer Research and currently is on the Board of Directors of the American Association of Cancer Institutes. He was also a member of the Medical Advisory Board of the Gairdner Foundation.
Job Titles:
- Member of the Senior Leadership Team
- Vice President of Global and U.S. Value and Market Access Strategy
Mr. Lanoue is Vice President of Global and U.S. Value and Market Access Strategy at Arvinas. He has over 20 years of experience in the pharmaceutical industry, including significant experience in marketing and market access with a focus on oncology.
Mr. Lanoue joins Arvinas from Novartis, where he spent the past 24 years in roles of increasing responsibility in research, marketing, and market access. Most recently, he was a Global Disease Leader for Value and Access where his team was responsible for global reimbursement and pricing for the breast and women's cancers product portfolio. Prior, he played an integral part in the launch of KISQALI®, a blockbuster treatment for advanced breast cancer, leading the development and execution of the Global Value and Access launch strategy for this key compound. He also held significant marketing leadership roles in the Global launch of ZYKADIA® and the U.S. launch of AFINITOR®.
Mr. Lanoue received his M.Sc. with a specialization in Developmental Genetics, and a B.Sc. in Biology, both from McMaster University in Hamilton, Ontario, Canada.
Job Titles:
- Member of the Senior Leadership Team
- Vice President, Global Development Operations
Mr. Romano serves as Vice President, Global Development Operations at Arvinas. He has more than 20 years of global experience in various clinical functions including leading development, outsourcing and operations. Mr. Romano joined Arvinas from Q32 Bio Inc, where he served as Senior Vice President, Clinical Development and Operations, and was responsible for growing the research-focused biotech into a company with first-in-human trials and Phase 2 plans.
Prior, Mr. Romano was Senior Vice President, Clinical Operations and Medical Affairs at Peachtree BioResearch Solutions, Inc., where he led a rapidly growing clinical team. Additionally, he held various clinical operations roles of increasing responsibility at companies including Clearside Biomedical, Inc., Amniox Medical Inc., Aderans Research Institute, Saint Joseph's Translational Research Institute, Alaven Pharmaceuticals LLC, UCB Pharma Inc., Pfizer, and Boehringer Ingelheim Pharmaceuticals.
Mr. Romano received his B.Sc. in Biology from The State University of New York and his M.A. in Public Health from Liberty University.
Job Titles:
- Member of the Senior Leadership Team
- Vice President, Intellectual Property
Mr. Beck is Vice President, Intellectual Property at Arvinas. He has over 20 years of experience building IP portfolios, guiding IP transactions, and setting IP strategies for life science companies.
Mr. Beck joins Arvinas after serving as Vice President and Head of Intellectual Property at Akebia Therapeutics where he led Akebia's IP team, developed the IP strategy for both commercial products and clinical stage assets, and directed U.S. and international IP litigation and adversarial proceedings.
Prior to Akebia, Mr. Beck held several positions within the Danaher family of companies, most recently as Chief IP Counsel of the Danaher Innovation Center, which made investments in emerging technologies in the life science and diagnostics fields.
Prior to that, Mr. Beck served as Chief IP Counsel at Forum Pharmaceuticals and Senior Patent Counsel at Genzyme Corporation.
Mr. Beck received his B.S. in Chemistry from The Ohio State University, his Ph.D. in Chemistry from Yale University, and his J.D. from George Washington University Law School.
Job Titles:
- Chief Accounting Officer
- Corporate Controller
- Member of the Senior Leadership Team
- Vice President
Mr. Loomis is Vice President, Corporate Controller and Chief Accounting Officer at Arvinas. He has nearly 30 years of finance experience in a variety of practices and industries, including the "Big Four" public accounting firms, general financial services and consulting, and the manufacturing industry, with the last 15 years spent in the biotech sector in the New Haven area.
Mr. Loomis joins Arvinas after serving as Vice President and Corporate Controller at Biohaven, where he was responsible for corporate tax, accounting, reporting, treasury, budgeting, and forecasting. As one of Biohaven's earliest employees, David supported their initial public offering, follow-on offerings, IP transactions, establishment of commercial processes and acquisitions, culminating with the $11.6B sale of their Calcitonin gene-related peptide (CGRP) business to Pfizer.
Mr. Loomis received his bachelor's degree and M.B.A. from Quinnipiac University in Hamden and is a Certified Public Accountant in the State of Connecticut.
Job Titles:
- Professor of Neurology at Harvard Medical School
Dr. Bradley Hyman is the John B. Penney, Jr. Professor of Neurology at Harvard Medical School and Massachusetts General Hospital. He directs the Alzheimer's disease research unit at the Mass General Institute for Neurodegenerative Diseases (MIND), with the goal of understanding the neuropathophysiological and genetic factors that underlie dementia. Dr. Hyman's laboratory studies the anatomical and molecular basis of dementia in Alzheimer's disease and dementia with Lewy bodies, with the goal of understanding the biology of dementias, how genetic risk factors impact these diseases, and how to develop new therapies that may help patients. Dr. Hyman earned his undergraduate degree from Northwestern University and received his M.D. and Ph.D. from the University of Iowa. He has been a recipient of the Metropolitan Life Award, the Potamkin Prize, a National Institute on Aging Merit award, and an Alzheimer's Association Pioneer Award. He is the current Director of the Massachusetts Alzheimer's Disease Research Center.
Job Titles:
- Member of the Audit Committee
- Chief Executive Officer of Crossbow Therapeutics
- Nominating and Corporate Governance Committee
Dr. Briggs Morrison is Chief Executive Officer of Crossbow Therapeutics and was President, Head of R+D at Syndax Pharmaceuticals, and is an Executive Partner at MPM Capital. Prior to joining Syndax Pharmaceuticals, he joined Merck & Co., Inc. and was appointed Head of Clinical Development at Pfizer. Additionally, Dr. Morrison became Head of Global Medicines Development and Chief Medical Officer at AstraZeneca. Dr. Morrison has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas, from first-in-human trials through to global regulatory approvals.
He is currently a board member of Carisma Therapeutics, Syndax Pharamceuticals, Werewolf and Repare Therapeutics and is an advisor to several other private biotechnology companies. Dr. Morrison received his B.S. in Biology from Georgetown University, his M.D. from the University of Connecticut Medical School, completed residency training in Internal Medicine at the Massachusetts General Hospital, and completed a fellowship in Medical Oncology at Dana-Farber Cancer Institute. He did postdocs with Philip Leder at Harvard Medical School, and Lee Nadler at the Dana-Farber Cancer Institute.
Job Titles:
- Member of the Senior Leadership Team
- Vice President of Pharmacovigilance
Dr. Christina Sheil serves as Vice President of Pharmacovigilance at Arvinas. Dr. Sheil has over 17 years of Pharmacovigilance experience in both pharmaceutical and biotechnology settings. Dr. Sheil joins Arvinas after serving as the Head of Pharmacovigilance at Taiho Oncology, where she was responsible for leading the Pharmacovigilance Medical and Pharmacovigilance Operational teams. Dr. Sheil built a fully functioning Global Pharmacovigilance organization, upgrading the department from the regional model that was formerly in place.
Prior to joining Taiho Oncology, Dr. Sheil was Executive Director and Head of Pharmacovigilance at Celldex Therapeutics, where she built the Pharmacovigilance function in a small biotech setting. Dr. Sheil also served as Global Head of Pharmacovigilance at Covance Inc., a large Contract Research Organization, as well as at Bracco Diagnostics, where she continued to build and improve department functioning globally for both organizations. She also has medical Pharmacovigilance experience serving as a Global Safety Officer early in her career at Sanofi, MedImmune, and Novartis, giving her both extensive pharmacovigilance medical and operational experience. Prior to joining the pharmaceutical industry, Dr. Sheil also worked at BioLife Plasma Services, where she was responsible for providing emergency medical oversight for patients, as well as completing all quality assurance deliverables for Good Clinical Practice (GCP), Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) Compliance.
Dr. Sheil received her M.D. from Rutgers University and, after residency, practiced clinically for over 13 years in addition to subsequently owning her own private practice for six years.
Job Titles:
- Chief Scientific Officer
- Member of the Executive Committee
Dr. Ian Taylor serves as the Chief Scientific Officer at Arvinas. Prior to joining Arvinas, Dr. Taylor served a decade at Pfizer Oncology as an Early Development Team Leader. During this time, Dr. Taylor was responsible for leading a cross-functional drug development team that conducted Phase 1 and Phase 2 clinical trials for multiple assets in several cancer indications. He also served as Senior Director of Translational Oncology, where he was responsible for directing translational science activities, which included designing and executing translational research plans and leading companion diagnostic partnerships for programs in both preclinical and clinical (Phase 1 -3) stages.
Dr. Taylor also worked at Bayer Healthcare Pharmaceuticals, holding positions of increasing responsibility, including Vice President of Cancer Biology, where he led biology aspects of small molecule drug discovery of cancer therapeutics in the mechanistic areas of signal transduction, cell cycle regulation, angiogenesis and apoptosis.
During his tenure, the Cancer Biology group delivered numerous molecules to the Development organization. He also started and led the Biomarker group, which contributed to the development of sorafenib.
Dr. Taylor earned his B.A. from Bowdoin College and his Ph.D. in Molecular Biology and Genetics from Harvard University. He also completed his postdoctoral training in the laboratory of Dr. Harold Varmus at the University of California, San Francisco and the National Institutes of Health (NIH).
Job Titles:
- Member of the Senior Leadership Team
- Vice President of Medicinal Chemistry
- Vice President, Discovery, Chemistry
Dr. Larry Snyder serves as Vice President of Medicinal Chemistry at Arvinas. Dr. Snyder joined Arvinas in 2015 after more than 20 years in the biopharmaceutical industry.
Prior to joining Arvinas, Dr. Snyder worked at Bristol-Myers Squibb where he led programs in the antibacterial, antiviral, and neuroscience therapeutic areas. Under Dr. Snyder leadership, the potential for discovering a novel treatment and cure for hepatitis C was realized, leading to the marketed novel NS5A protein inhibitor, Daklinza®.
At Arvinas, Dr. Snyder led the chemistry effort resulting in the discovery of ARV-110 and ARV-776,, Arvinas' orally bioavailable novel PROTAC® protein degraders for the treatment of men with metastatic castration resistant prostate cancer.
Dr. Snyder received his Ph.D. from Colorado State University under the direction of the late Albert I. Meyers and did his post-doctoral training at Memorial Sloan Kettering Cancer Center under Samuel J. Danishefsky.
Job Titles:
- Professor and Chair of Pharmaceutical Chemistry
Dr. Michelle Arkin is a chemical biologist, Professor and Chair of Pharmaceutical Chemistry, and Director of the Small Molecule Discovery Center (SMDC) at the University of California, San Francisco (UCSF). Dr. Arkin's research focuses on developing methods and molecules that target currently ‘undruggable proteins,' including protein-protein interactions and dynamic or intrinsically disordered proteins. The SMDC engages in collaborative drug discovery research, capitalizing on tools and expertise in high-throughput screening, fragment-based drug discovery, and medicinal chemistry. Dr. Arkin is an investigator in the UCSF Cancer Center, the Tau Consortium, and the Bakar Aging Research Institute, and is an Adjunct Professor at the Buck Institute for Research in Aging. She is involved with the academic drug discovery community, as Director and former President of the Academic Drug Discovery Consortium, Fellow and former Director of the Society for Laboratory Automation and Screening, and editor of the National Institutes of Health Assay Guidance Manual. Dr. Arkin is a cofounder and Director of Ambagon Therapeutics and cofounder of Elgia Therapeutics.
Job Titles:
- Chief Medical Officer
- Member of the Executive Committee
Dr. Noah Berkowitz is Chief Medical Officer at Arvinas and responsible for clinical development of the company's PROTAC® protein degrader programs in oncology and neuroscience. Dr. Berkowitz has more than 20 years of experience in advancing programs through early and late stages of development, with proven ability in leading clinical development, regulatory, and medical affairs. He has led multidisciplinary teams and has extensive knowledge of clinical trial design and execution.
Prior to joining Arvinas, Dr. Berkowitz was Senior Vice President and Development Unit Head of Hematology at Bristol-Myers Squibb (BMS). While at BMS, Dr. Berkowitz's teams achieved initial or subsequent global indications for Abecma®, Breyanzi®, Reblozyl®, Onureg®, and Inrebic®, managed development life cycles for Revlimid®, Pomalyst®, and Sprycel®, and initiated and/or designed registration trials for iberdomide, mezigdomide, and alnuctamab. Before BMS, Dr. Berkowitz held roles of increasing responsibility in the areas of oncology, rare diseases, and hematology at Novartis, most recently as Vice President and Clinical Development Head for Hematology. Earlier in his career, Dr. Berkowitz was an executive at Impath (acquired by Genzyme) and founder and Chief Executive Officer of Synvista.
Dr. Berkowitz trained in Medical Oncology at the National Cancer Institute and received his M.D., Ph.D., from Columbia University.
Job Titles:
- Interim Chief Financial Officer
- Member of the Executive Committee
- Treasurer
Dr. Randy Teel serves as interim Chief Financial Officer & Treasurer at Arvinas. In addition, Dr. Teel is responsible for corporate strategy, business development, investor relations, and communications.
Previously, Dr. Teel was Vice President and Head of Strategy at Alexion Pharmaceuticals, where he was responsible for long-range planning, partnering with the R&D and Commercial organizations as they developed inline and lifecycle management strategies. Dr. Teel also led enterprise risk management and numerous strategic initiatives across the company. Prior to Alexion, Dr. Teel was an Associate Partner at McKinsey & Company, where he advised biopharmaceutical clients on issues in commercial, medical, and development. Dr. Teel currently serves on the board of directors at Oerth Bio.
Dr. Teel received his B.Sc. in Biology at Gonzaga University and his Ph.D. in Immunobiology from Yale University.
Job Titles:
- Member of the Audit Committee
- Member of the Board of Directors
- Nominating and Corporate Governance Committee
Dr. Sunil Agarwal recently served as Executive Vice President, Head of Development and Chief Medical Officer at Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines for patients.
Prior to this, Dr. Agarwal served as President of Research and Development at Juno Therapeutics. He also served as a former Executive Vice President and Chief Medical Officer at Ultragenyx Pharmaceutical where he managed the company's clinical development and operations, regulatory affairs, biometrics, pharmacovigilance, medical affairs, pharmacology, and toxicology functions. Additionally, Dr. Agarwal previously served in various increasing leadership roles at Genentech for more than a decade, including Senior Vice President and Global Head of Clinical Development for ophthalmology, metabolism, neurosciences, immunology, and infectious diseases. He led the approvals and line extensions of multiple therapies at Genentech including RITUXAN, ACTEMRA, LUCENTIS and XOLAIR.
Dr. Agarwal completed his residency at Children's National Medical Center (CNMC), Washington, D.C., and practiced in the CNMC Pediatric Emergency Department. He obtained his B.S. in neurobiology from Cornell University and earned his M.D. from Tufts University School of Medicine.
Job Titles:
- Director
- Member of the Audit Committee
- Compensation Committee
Dr. Wendy Dixon is the Director for Black Diamond Therapeutics. She previously served as a Director of Alkermes, Ardea
Biosciences, Bluebird bio, Dentsply International, Furiex Pharmaceuticals, Incyte, Iovance Biotherapeutics, Orexigen Therapeutics, Sesen Bio, and Voyager Therapeutics. Additionally, she served as an Independent Director for Edimer Therapeutics, a private company. From 2001 to 2009, Dr. Dixon was Chief Marketing Officer & President of Global Marketing at Bristol Myers Squibb, as well as a member of the CEO's Executive Committee. Prior to this she served as Senior Vice President of Marketing for Merck & Co., Inc. Dr. Dixon also held senior vice president roles at West Pharmaceuticals, Osteotech, Inc., Centocor, Inc., and Smith Kline & French Pharmaceuticals.
Throughout her career in the pharmaceutical and biotechnology industries, Dr. Dixon has been responsible for building and leading organizations, and launching and growing more than 20 pharmaceutical products, including Tagamet, Fosamax, Singulair, Plavix, Abilify, Reyataz and Baraclude. Dr. Dixon received her B.Sc., M.Sc. and Ph.D. from the University of Cambridge, UK.
Job Titles:
- Member of the Audit Committee
- Member of the Board of Directors
- Nominating and Corporate Governance Committee
Job Titles:
- Member of the Senior Leadership Team
- Senior Vice President, Early Clinical Development
Job Titles:
- Member of the Audit Committee
- Member of the Board of Directors
- Audit Committee
- Chief Commercial Officer of Exact Sciences
Mr. Cunningham is Chief Commercial Officer of Exact Sciences. He has over 35 years of progressive responsibility in pharmaceuticals and medical services. Prior to joining Exact Sciences, Mr. Cunningham served as President & CEO of GE Healthcare's U.S. & Canada regions. Before joining GE, Mr. Cunningham served as the Senior Vice President, Commercial, at Quest Diagnostics, where he was responsible for global commercial sales, marketing, and commercial operations. Mr. Cunningham also served in numerous senior leadership roles at Pfizer, including Regional President, Established Products for Asia Pacific, Senior Director of Worldwide Learning and Development, Senior Director of Business Operations, Vice President Sales for U.S. Pharmaceuticals, and Vice President of Global Corporate Human Resources.
Mr. Cunningham has served on the board of American Family Children's Hospital in Madison, WI, since 2021, and Visby Medical in San Jose, CA, since 2022. He earned his bachelor's degree in economics from Northwestern University.
Job Titles:
- Member of the Senior Leadership Team
- Vice President and Head of Translational Sciences, Oncology
Dr. Wang is Vice President and Head of Translational Sciences, Oncology at Arvinas. She has more than 25 years of experience in both industry and academia and an impressive track record of driving impactful contributions in clinical development in oncology and immuno-oncology. Dr. Wang has led research and development teams focusing on translational sciences and precision medicine at pharmaceutical and biotechnology companies for the past 16 years.
Dr. Wang previously served as Senior Director at EMD Serono, a subsidiary of Merck KGaA, where she was Head of Companion Diagnostics (CDx), Clinical Biomarker Expert Team Lead and Department U.S. Site Head, where she oversaw clinical biomarker and CDx strategy and activities from early- to late-stage of clinical development, global regulatory submission and approval, and life cycle management in oncology and immuno-oncology programs.
Prior to this, Dr. Wang was the Head of Protein Diagnostics Development and Technical Lead at Novartis where her team was responsible for end-to-end CDx product development and delivery, as well as overarching clinical biomarker strategy in oncology and immuno-oncology programs.
Dr. Wang received her Ph.D. in Biochemistry from Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing and her M.S.c. and B.S.c. degrees in Cell Biology from Lanzhou University, China. After she completed her postdoctoral fellowship, Dr. Wang was an instructor in the laboratory of Dr. Alan D. D'Andrea at the Dana-Farber Cancer Institute, Harvard Medical School.
Job Titles:
- Member of the Senior Leadership Team
- Vice President, Estrogen Receptor Global Asset Lead
Jared Freedberg - Chief Legal Officer, Secretary
Job Titles:
- Corporate Secretary
- General Counsel
- Member of the Executive Committee
Job Titles:
- Member of the Senior Leadership Team
- Vice President of Investor Relations
Mr. Boyle serves as Vice President of Investor Relations at Arvinas. Mr. Boyle is responsible for leading our investor relations strategy and liaising with the investor community, including sell-side and buy-side analysts, industry analysts, and investors worldwide. Prior to joining Arvinas, Mr. Boyle spent nearly five years at Sage Therapeutics, where he led the development and execution of an integrated investor relations and communications strategy, most recently as Vice President of Investor Relations. With more than 15 years of experience in investor relations and communications within the biotechnology industry, he increased responsibility at BIND Therapeutics and Biogen. Mr. Boyle received a B.A. in Finance from the University of Colorado.
Job Titles:
- Member of the Senior Leadership Team
- Senior Vice President of R & D Technical Operations
Dr. John Grosso serves as Senior Vice President of R&D Technical Operations at Arvinas. Dr. Grosso brings both deep and broadly diversified pharmaceutical development and manufacturing experience to the Company, having led process chemistry, analytical, and drug development functions both in large pharma and in biotech.
Prior to joining Arvinas, Dr. Grosso was Executive Director and Head of Pharmaceutical Development at Vitae Pharmaceuticals where he was responsible for API and DP development and manufacturing as well as Clinical Supply. During the two years spent at Vitae, he advanced two oral RORƴt antagonists and one LXR agonist into the clinic.
Dr. Grosso began his career with Bristol-Myers Squibb in Chemical Process R&D rising to the level of Director and site-head for PR&D over a twenty-year span. He transitioned into Analytical R&D where, as Executive Director, he was responsible for process analytical science, method development and testing for both API and DP, in addition to a number of specialty labs. He finished his tenure at BMS as Executive Director, Drug Product Science and Technology. Over his 32-year career at BMS he played a pivotal role in the development and commercialization of Monopril®, Taxol®, Eliquis®, Sprycel®, and Dapagliflozin®
Dr. Grosso earned his undergraduate degree in Chemistry at New York University, and his Ph.D. in Medicinal Chemistry at Purdue University.
Job Titles:
- Chairman of the Executive Committee
- Chief Executive Officer
- Member of the Board of Directors
- President
Dr. John Houston serves as Chairperson, Chief Executive Officer, and President at Arvinas. With over 30 years of experience, he served as the Senior Vice President of Specialty Discovery at Bristol Myers Squibb (BMS). He spent more than 18 years at BMS in roles of increasing responsibility and had accountability for all Discovery Biology disease teams as well as various Discovery technology departments. Dr. Houston was a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee, which had governance oversight in the discovery space. With his teams and research colleagues, he progressed over 200 compounds into early development, several of which advanced into late-stage clinical trials and toward commercialization.
Prior to joining Bristol Myers Squibb, he worked at Glaxo Wellcome Research and Development in the UK, where he served as head of the Lead Discovery Unit. Dr. Houston currently serves on the boards of directors of NextCure, Inc., Oerth Bio, Cybrexa Therapeutics and BioCT.
Dr. Houston obtained his B.Sc. degree in Medical Microbiology from Glasgow University and obtained his Ph.D. in Microbial Biochemistry from Heriot-Watt University, Edinburgh. He also completed his post-doctoral studies on an MRC grant at Glasgow University.
Job Titles:
- Chief Commercial Officer
- Member of the Executive Committee
Mr. Northcott serves as Chief Commercial Officer at Arvinas. Mr. Northcott has extensive U.S. and global commercial leadership experience, including both pre-launch planning and on-market commercialization in oncology and other therapeutic areas. Prior to Arvinas, Mr. Northcott served as Chief Commercial Officer of Nektar Therapeutics. From 2015 to 2019, he served as the Chief Commercial Officer of Pharmacyclics, where he led the successful commercialization of Imbruvica®, with functional responsibility for commercial strategy, marketing, market access, sales, analytics, and commercial operations.
From 2013 to 2015, Mr. Northcott was Chief Commercial Officer at Lexicon Pharmaceuticals where he led commercial strategy and operations for all products and therapeutic areas. From 2007 to 2013, Mr. Northcott held commercial leadership roles in both U.S. and global marketing for Avastin® with Genentech and the Roche Group. Additionally, Mr. Northcott held prior management positions in sales and marketing in a variety of therapeutic areas at pharmaceutical companies including Merck and Pfizer.
Mr. Northcott received his B.A. in Business Administration from St. Francis Xavier University.
Job Titles:
- Member of the Senior Leadership Team
- Vice President, Androgen Receptor Global Asset Lead
Job Titles:
- Member of the Audit Committee
- Compensation Committee
Mr. Young most recently served as Group President and Senior Advisor to the Pfizer CEO prior to his retirement from Pfizer in mid-2022. Mr. Young has been a distinguished member of several boards over the years. He currently serves on the Boards of Johnson Controls International (JCI), Novartis AG (NVTS), and Imbria Pharmaceuticals. Mr. Young previously served on the Boards of Haleon
Job Titles:
- Member of the Executive Committee
- Senior Vice President, Global Head of Oncology Strategy and Program Leadership
Job Titles:
- Member of the Senior Leadership Team
- Vice President, Information Technology and Corporate Projects
Job Titles:
- Member of the Audit Committee
- Compensation Committee
Job Titles:
- Member of the Audit Committee
- Audit Committee
Ms. Norwalk provides strategic counsel to a wide spectrum of healthcare corporations and biotechnology companies. She works in the Washington, D.C. office of Epstein Becker Green, P.C., and serves as strategic counsel to Epstein Becker Green, P.C., EBG Advisors and National Health Advisor. She also serves as an advisor to private equity firms. She currently sits on the boards of directors of ModivCare, Neurocrine Biosciences, and NuVasive, and several privately held healthcare companies. Additionally, Ms. Norwalk sits on APCO Worldwide's International Advisory Council.
Prior to her work as an advisor, Ms. Norwalk served in the George W. Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services (CMS). She managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities, and other federal health care initiatives. For four years prior to that, she was the agency's Deputy Administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. Prior to serving the Bush Administration, she practiced law in the Washington, D.C., office of Epstein Becker Green, where she advised clients on a variety of health policy matters. She also served in the first Bush Administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative.
Ms. Norwalk earned a juris doctor degree from the George Mason University School of Law, where she was a Dean's Scholar and an editor of the George Mason Law Review. She earned a bachelor's degree, cum laude, in economics and international relations from Wellesley College.
Dr. Lillian Siu is a senior medical oncologist at the Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto. She is the Co-Principal Investigator of the Ontario Institute for Cancer Research-supported Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) study. Dr. Siu is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at the Princess Margaret Cancer Centre and holds the BMO Chair in Precision Cancer Genomics. She is the clinical lead for the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre, where she has been leading genomics initiatives and immuno-oncology trials. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016), as a member of the Nomination Committee for the American Association of Cancer Research (AACR, 2014-2016), and on the AACR Board of Directors for a three-year term (2017-2020).
Job Titles:
- Member of the Audit Committee
- Member of the Board of Directors
- Audit Committee
- Chief Operating Officer and Chief Financial Officer for Mariana Oncology
Ms. Bain serves as Chief Operating Officer and Chief Financial Officer for Mariana Oncology. She brings extensive experience in strategic planning, finance, transactions, operations, investor relations, corporate communications and program management.
Previously, Ms. Bain served as Chief Financial Officer of Codiak BioSciences. Prior to that she was Chief Financial Officer of Avalanche Biotechnologies, where she led a successful initial public offering (IPO) and follow-on financing. Additionally, she served as Vice President of Finance, Business Operations, and Treasurer at bluebird bio, where she led a successful IPO.
Ms. Bain also held senior roles at Genzyme Corporation where she was Vice President of Finance, Global Manufacturing and Operations, and Vice President of Finance, Genzyme Genetics. Earlier in her career, she held senior roles at Fidelity Investments, AstraZeneca, and Deloitte & Touche.
Ms. Bain currently serves on the Board of Directors of Autolus Therapeutics and Hemab Therapeutics. She is a Certified Public Accountant and earned a Bachelor of Science in Accounting and Business Administration, as well as an Honors degree in Accounting and Business Administration, from the University of the Free State, Bloemfontein, South Africa.
Job Titles:
- Member of the Executive Committee
- Senior Vice President, Corporate Operations
Ms. Sinclair is Senior Vice President, Corporate Operations at Arvinas. Ms. Sinclair has more than 25 years of biopharmaceutical experience, specializing in strategic operations, portfolio management, and new product development planning from preclinical to launch.
Prior to joining Arvinas, Ms. Sinclair served as Head of Corporate and Commercial Strategy at Rallybio, where she led strategic and operational planning, including market landscape assessments, sustainable pipeline analyses, approaches to portfolio growth, development of corporate goals and priorities, capability planning frameworks, and scenario planning.
Previously, Ms. Sinclair served as the Head of Program and Alliance Management for SpringWorks Therapeutics, where she was responsible for operational planning, life cycle strategy, and alliance collaborations. She also served as Vice President of R&D Strategy and Portfolio and Project Management at Alexion AstraZeneca Rare Disease, where she led generation of the long-term R&D strategy and built portfolio capabilities that informed investment in the pipeline and external opportunities in rare disease. Prior to Alexion, Ms. Sinclair was Vice President of Global R&D Portfolio and Performance at AstraZeneca, and she spent 18 years at Pfizer in various roles of increasing responsibility in R&D and commercial.
Ms. Sinclair began her career in marketing for the packaging industry and received a Bachelor of Arts in business administration with a concentration in marketing from the University of Vermont.
Job Titles:
- Member of the Senior Leadership Team
- Vice President and Head of Medical Affairs
Job Titles:
- Member of the Executive Committee
- Senior Vice President, Regulatory Affairs
Paul McInulty is Senior Vice President, Regulatory Affairs at Arvinas. Mr. McInulty has over 25 years of experience in both small and large pharmaceutical companies leading all aspects of regulatory affairs with significant clinical regulatory strategy leadership expertise. Mr. McInulty joined Arvinas after serving as Vice President, Therapeutic Head, Hematology and Precision Medicines Regulatory Affairs at Bristol Myers Squibb where he led a regulatory team responsible for hematology indications and precision medicine and drove the regulatory strategy and implementation of activities needed to secure approval of new drugs and expanded indications across the hematology product portfolio.
Previously, Mr. McInulty spent 15 years at Celgene Corporation in various roles of increasing responsibility including serving as Vice President, Regulatory Affairs, Hematology/Oncology where he led the regulatory team responsible for Hematology/Oncology Indications, including all cell therapy programs.
Mr. McInulty received his B.Sc. in Pharmacology from the University of Sheffield, Department of Pharmacology.
Job Titles:
- Member of the Senior Leadership Team
- Vice President of Global and U.S. Commercial Analytics
Sharvari Apte is Vice President of Global and US Commercial Analytics at Arvinas. Ms. Apte has over 15 years of experience in Commercial Analytics and Insights, supporting pipeline, pre-launch and on-market products in oncology and other therapeutic areas.
Ms. Apte came to the company after serving as Executive Director, Market Research and Analytics at Nektar Therapeutics, where she built the company's commercial insights and analytics capabilities to support commercial launch readiness activities.
Previously, Ms. Apte was at Genentech where she led insights and analytics teams in oncology as well as other therapy areas. Prior to that she worked as a sales and marketing consultant at ZS Associates, supporting several global and US-based pharmaceutical and biotech clients.
Ms. Apte received her B.S. in Engineering from the University of Mumbai, India and her M.S. in Operations Research from the University of California, Berkeley.
Job Titles:
- Member of the Senior Leadership Team
- Vice President of Quality and Environmental Health & Safety
Ms. Diaz is Vice President of Quality and Environmental Health & Safety at Arvinas. She has 30 years of diverseQuality experience in the biopharmaceutical industry where she has led global Quality teams within the clinical and commercial stages in support of start-ups, mergers and acquisitions, joint ventures, and strategic business partnerships
Ms. Diaz joins Arvinas after roles of increasing responsibility including Senior Director, Head of Quality North America, Senior Director, Head of Quality North America LATAM & APAC and Senior Director, Head of Quality North AmericaUS & Canada at Swedish Orphan Biovitrum AB, an international biopharmaceutical company dedicated to treatments in the areas of hematology, immunology, and specialty care.
Prior to this, Ms. Diaz served as Director, Head of Quality at Dova Pharmaceuticals, Inc. Additionally, she previously served in various increasing leadership roles including Site Quality Head, Quality Assurance at Purdue Pharmaceuticals, LP, Associate Director, Global Supplier Quality & Quality Compliance at ConvaTec, Inc. and Senior Manager, Global Supply Assurance and Optimization Leader at TEVA Pharmaceuticals.
Ms. Diaz received her bachelor's degree in Health Sciences from Campbell University, her Master of Science degree in Regulatory Affairs for Drugs, Biologics and Medical Devices from Northeastern University and will receive her Juris Doctor degree from Taft University Law School this year.
Job Titles:
- Member of the Senior Leadership Team
- Vice President of Global and U.S. Marketing for Breast Cancer
Mr. Sekhar is Vice President of Global and U.S. Marketing for Breast Cancer at Arvinas. He has over 20 years of experience in the pharmaceutical industry, with 15 of those years in marketing focused on oncology, leading numerous new product launches across both hematology and solid tumors.
Mr. Sekhar was previously at Bristol Myers Squibb where he held roles of increasing responsibility across commercial and development, including serving as U.S. Vice President, Marketing for Myeloid Diseases and Worldwide Vice President, Marketing for Myeloid Diseases.
Prior to that, Mr. Sekhar held several roles at Celgene Corporation, AstraZeneca, and Accenture.
Mr. Sekhar received his B.S. from Rutgers University and an M.B.A. from the University of Pennsylvania's Wharton School of Business.
Job Titles:
- Chief Human Resources Officer
- Member of the Executive Committee
- Senior Vice President
Mr. Weiss serves as the Senior Vice President and Chief Human Resources Officer at Arvinas and is responsible for overseeing all aspects of human resources, including talent acquisition, total rewards, organization and leadership development, diversity and inclusion, and engagement. With over 25 years of global experience in diverse industries, Mr. Weiss has achieved results within biotechnology, diagnostic imaging, asset management, legal and financial services.
Prior to joining Arvinas, Mr. Weiss served as Executive Director, Human Resources at Alexion Pharmaceuticals. In this role, he led the delivery of strategic human resource programs and solutions across multiple corporate functions, including finance, IT, legal, compliance, government affairs, business development and strategy. Prior to Alexion Pharmaceuticals, he was Assistant Vice President with Hartford Investment Management, and he held roles of increasing responsibility previously at United Technologies, General Electric and Sullivan & Cromwell.
Mr. Weiss holds a B.Sc. degree from the University of Kansas.
Job Titles:
- Member of the Senior Leadership Team
- Vice President and Head of Nonclinical Sciences